Patients with neurodegenerative ataxia that are treated with cerebello-spinal transcranial direct current simulation (tDCS) have significant improvements in gait, upper limb coordination, quality of life, and other neurological evaluations of cerebellar deficits, according to results from the CStDCSAtaxia trial.
Patients with neurodegenerative ataxia that are treated with cerebello-spinal transcranial direct current simulation (tDCS) have significant improvements in gait, upper limb coordination, quality of life, and other neurological evaluations of cerebellar deficits, according to results from the CStDCSAtaxia trial.
Sporadic and hereditary neurodegenerative ataxias are disabling diseases associated with tremors, dysarthria, and cognitive decline, with no effective treatments. Cerebral tDCS have shown improvements in the posture, gait, and kinetic functions in patients with ataxia. In addition to cerebral tDCS, spinal tDCS targeting neurodegeneration of spinal cord structures have also shown promising results in patients with spinal cord injuries. Because ataxia can cause degeneration in both cerebral and spinal cord, stimulation of both structures may help more than 1 stimulation alone. The purpose of the CStDCSAtaxia trial is to evaluate cerebello-spinal tDCS and its long-term effects in patients with neurodegenerative ataxia.
Read how poor sleep patterns in patients with MS leads to anxiety, depression.
Patients with neurodegenerative ataxia received either concurrent stimulation of anodal cerebellar tDCS and cathodal spinal tDCS or sham stimulation for 2 weeks and were monitored for 3 months. Following an additional washout period of 3 months, each patient received the opposite treatment and underwent the same assessment as before. Improvements in ataxia were assessed through 2 clinical scales:
Upper limb coordination was gauged through the 9-Hole Peg Test (9HPT), a test to check finger dexterity, while gait speed was evaluated through the 8-m walking time. A Short-Form Health Survey 36 (SF-36) was used to access quality of life.
SARA scores revealed a significant difference between treatment with tDCS versus sham stimulation at 2 weeks, 1 month, and 3 months (P < .001), but not at baseline (P = .422). ICARS scores also showed significant differences at 2 weeks, 1 month, and 3 months (P < .001), but not at baseline (P = .613). Individual assessment of the ICARS scale reviewed statistically significant differences in the posture/gait (P = .011) and limb coordination (P < .001), but not statistically significant for dysarthria (P =.235) or oculomotor movement (P = 1).
9HPT revealed a significant difference between tDCS treatment and sham stimulation in both the dominant and nondominant hand at 2 weeks, 1 month, and 3 months (P < .001) but not at baseline (dominant P = .670; nondominant P = .926). A significant improvement found in the 8-minute walking time was correspondingly seen at each endpoint (P < .05), and not for baseline (P = .414). A significant improvement in SF-36 scores (P < .05) at all endpoints except for baseline (P = .775) was seen in the tDCS treatment group, but not the sham stimulation group. Finally, cerebellar brain inhibition revealed significant increases in average resting motor cortex thresholds in the tDCS treatment group at all endpoints except for baseline, and none in the sham stimulation group.
Current pharmacologic and nonpharmacologic therapies for neurodegenerative ataxia are limited, with many patients having debilitating clinical symptoms. Treatment with cerebello-spinal tDCS seems to have a significant effect in helping patients with neurodegenerative ataxia and could be viewed as a potential line of treatment for rehabilitation.
Reference
Benussi A, Dell’Era V, Cantoni V, et al. Cerebello-spinal tDCS in ataxia a randomized, double-blind, sham-controlled, crossover trial. Neurology. 2018;91:1-12. doi:10.1212/WNL.0000000000006210.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More